The Journal of Korean Diabetes (당뇨병)

Korean Diabetes Association (대한당뇨병학회)
권호 표지

Pharmachotherapy for Depressive Disorder in Patients with Diabetes Mellitus

당뇨병에서 우울증의 약물치료(주요 우울증과 항우울제를 중심으로)

Yoo, Hee-Jeong
유희정

  • Published : 2008.12.10
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Vieweg WV, Levy JR, Fredrickson SK, Chipkin SR, Beatty-Brooks M, Fernandez A, Hasnain M, Pandurangi AK: Psychotropic drug considerations in depressed patients with metabolic disturbances. Am J Med 121:647-55, 2008 https://doi.org/10.1016/j.amjmed.2007.08.043
  2. Lustman PJ, Clouse RE, Nix BD, Freedland KE, Rubin EH, McGill JB, Williams MM, Gelenberg AJ, Ciechanowski PS, Hirsch IB: Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 63:521-9, 2006 https://doi.org/10.1001/archpsyc.63.5.521
  3. Musselman DL, Betan E, Larsen H, Phillips LS: Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol Psychiatry 54:317-29, 2003 https://doi.org/10.1016/S0006-3223(03)00569-9
  4. Lustman PJ, Clouse RE: Depression in diabetic patients: the relationship between mood and glycemic control. J Diabetes Complications 19:113-22, 2005
  5. Lustman PJ, Clouse RE, Freedland KE: Management of Major Depression in Adults With Diabetes: Implications of Recent Clinical Trials. Semin Clin Neuropsychiatry 3:102-14, 1998
  6. Lustman PJ, Clouse RE: Treatment of depression in diabetes: impact on mood and medical outcome. J Psychosom Res 53:917-24, 2002 https://doi.org/10.1016/S0022-3999(02)00416-6
  7. Lustman PJ, Griffith LS, Freedland KE, Clouse RE: The course of major depression in diabetes. Gen Hosp Psychiatry 19:138-43, 1997 https://doi.org/10.1016/S0163-8343(96)00170-3
  8. Lustman PJ, Freedland KE, Griffith LS, Clouse RE: Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. Diabetes Care 23:618-23, 2000 https://doi.org/10.2337/diacare.23.5.618
  9. Lustman PJ, Griffith LS, Clouse RE, Freedland KE, Eisen SA, Rubin EH, Carney RM, McGill JB: Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial. Psychosom Med 59:241-50, 1997 https://doi.org/10.1097/00006842-199705000-00007
  10. Cole BE: Diabetic peripheral neuropathic pain: recognition and management. Pain Med 8 Suppl 2:S27-32, 2007 https://doi.org/10.1111/j.1526-4637.2007.00349.x
  11. Goodnick PJ: Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. Ann Clin Psychiatry 13:31-41, 2001 https://doi.org/10.3109/10401230109147127
  12. Westanmo AD, Gayken J, Haight R: Duloxetine: a balanced and selective norepinephrine- and serotonin -reuptake inhibitor. Am J Health Syst Pharm 62:2481-90, 2005 https://doi.org/10.2146/ajhp050006
  13. Sultan A, Gaskell H, Derry S, Moore RA: Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurol 8:29, 2008 https://doi.org/10.1186/1471-2377-8-29
  14. Himmerich H, Schuld A, Pollmacher T: [Weight gain during treatment with antipsychotics: clinical relevance, pathophysiology, and therapeutical strategies]. Psychiatr Prax 31 Suppl 2:S233-7, 2004 https://doi.org/10.1055/s-2004-828475
  15. Sussman N, Ginsberg DL, Bikoff J: Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine -controlled trials. J Clin Psychiatry 62:256-60, 2001 https://doi.org/10.4088/JCP.v62n0407
  16. Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Kim C, Lau J: Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis. Arch Intern Med 164:1395-404, 2004 https://doi.org/10.1001/archinte.164.13.1395
  17. Marcus MD, Wing RR, Guare J, Blair EH, Jawad A: Lifetime prevalence of major depression and its effect on treatment outcome in obese type II diabetic patients. Diabetes Care 15:253-5, 1992 https://doi.org/10.2337/diacare.15.2.253
  18. Goodnick PJ, Henry JH, Buki VM: Treatment of depression in patients with diabetes mellitus. J Clin Psychiatry 56:128-36, 1995
  19. Maheux P, Ducros F, Bourque J, Garon J, Chiasson JL: Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss. Int J Obes Relat Metab Disord 21:97-102, 1997 https://doi.org/10.1038/sj.ijo.0800372
  20. Potter van Loon BJ, Radder JK, Frolich M, Krans HM, Zwinderman AH, Meinders AE: Fluoxetine increases insulin action in obese type II (non-insulin dependent) diabetic patients. Int J Obes Relat Metab Disord 16 Suppl 4:S55-61, 1992
  21. O'Kane M, Wiles PG, Wales JK: Fluoxetine in the treatment of obese type 2 diabetic patients. Diabet Med 11:105-10, 1994 https://doi.org/10.1111/j.1464-5491.1994.tb00238.x
  22. Paile-Hyvarinen M, Wahlbeck K, Eriksson JG: Quality of life and metabolic status in mildly depressed patients with type 2 diabetes treated with paroxetine: a double-blind randomised placebo controlled 6-month trial. BMC Fam Pract 8:34, 2007 https://doi.org/10.1186/1471-2296-8-34
  23. Gulseren L, Gulseren S, Hekimsoy Z, Mete L: Comparison of fluoxetine and paroxetine in type II diabetes mellitus patients. Arch Med Res 36:159-65, 2005 https://doi.org/10.1016/j.arcmed.2004.12.018
  24. DeVane CL, Markowitz JS: Psychoactive drug interactions with pharmacotherapy for diabetes. Psychopharmacol Bull 36:40-52, 2002
  25. Tremaine LM, Wilner KD, Preskorn SH: A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide. Clin Pharmacokinet 32 Suppl 1:31-6, 1997 https://doi.org/10.2165/00003088-199700321-00005